1-(2-糠酰)哌嗪 | 40172-95-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-(2-糠酰)哌嗪
• 中文别名: 1-(2-呋喃基)哌嗪；2-糠酸哌嗪；N-(2-呋喃甲酰基)哌嗪；N-(2-糠酰基)哌嗪；1-(2-呋喃甲酰基)哌嗪；1-(2-糠酰基)哌嗪
• 英文名称: N-(furan-2-carbonyl)piperazine
• 英文别名: 1-(2-furoyl)piperazine；furan-2-yl(piperazin-1-yl)methanone
• CAS: 40172-95-0
• 化学式: C₉H₁₂N₂O₂
• mdl: MFCD00038831
• 分子量: 180.206
• InChiKey: SADPINFEWFPMEA-UHFFFAOYSA-N

物化性质

• 熔点：
  67-70 °C(lit.)
• 沸点：
  137-140°C 0,1mm
• 密度：
  1.1819 (rough estimate)
• 闪点：
  >230 °F
• 溶解度：
  可溶于氯仿、甲醇（少许）
• 稳定性/保质期：
  常规情况下不会分解，也没有危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  45.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2934999090
• 安全说明：
  S24/25,S26,S36
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  密封、阴凉、干燥保存。

SDS

Name:	1-(2-Furoyl)piperazine 98% Material Safety Data Sheet
Synonym:	1-(2-Furanylcarbonyl)-piperazin
CAS:	40172-95-0

Section 1 - Chemical Product MSDS Name:1-(2-Furoyl)piperazine 98% Material Safety Data Sheet
Synonym:1-(2-Furanylcarbonyl)-piperazin

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
40172-95-0	1-(2-Furoyl)piperazine	98	254-823-7

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
Causes eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
Causes skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
The toxicological properties of this substance have not been fully investigated. Causes gastrointestinal tract irritation.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid immediately. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate general or local exhaust ventilation to keep airborne concentrations below the permissible exposure limits. Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels.
Exposure Limits CAS# 40172-95-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Wear a NIOSH/MSHA or European Standard EN 149 approved full-facepiece airline respirator in the positive pressure mode with emergency escape provisions. Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149.
Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 68 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: N/A
Explosion Limits, upper: N/A
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H12N2O2
Molecular Weight: 180.21

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 40172-95-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(2-Furoyl)piperazine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 40172-95-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 40172-95-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 40172-95-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

制备方法：盐酸哌唑嗪中间体。

用途简介：暂无内容。

反应信息

• 作为反应物：
  描述：

  1-(2-糠酰)哌嗪 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 、 乙腈 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 反应 6.0h， 生成 [4-(4-amino-phenyl)-piperazin-1-yl]-furan-2-yl-methanone
  参考文献：
  名称：

  一系列基于咪唑的白色念珠菌抑制剂的合成，生物学评估和结构-活性相关性研究

  摘要：

  合成了一系列新的2-（1H-咪唑-1-基）-1-苯基乙醇衍生物。在体外评估了针对不同真菌种类的抗真菌活性。生物学结果表明，最具活性的化合物具有与氟康唑相当或更高的抗白色念珠菌，非白色念珠菌念珠菌，新隐球菌和皮肤真菌的抗真菌活性。由于它们的外消旋性质，测试了最具活性的化合物5f和6c为纯对映体。对于6c，（R）-对映体比（S）-1具有更高的活性，否则对于5f，（S）-对映体最活跃。为了合理化实验数据，进行了基于配体的计算研究。建模研究的结果表明（小号） - 5F和（- [R ）- 6c中完美到基于配体的模型对齐，表现出相同的相对构型。对人肺腺癌上皮细胞（A549）的初步研究表明，6c，5e和5f具有低细胞毒性。

  DOI：

  10.1016/j.ejmech.2014.07.001
• 作为产物：
  描述：

  糠酸（呋喃甲酸） 在 potassium carbonate 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 0.5h， 生成 1-(2-糠酰)哌嗪
  参考文献：
  名称：

  高亲和力和低 PARP 捕获苯并咪唑衍生物作为 PARP1 降解剂的潜在弹头

  摘要：

  PARPi已被探索并应用于治疗多种癌症，效果显着，特别是BRCA1/2突变的卵巢癌、乳腺癌、前列腺癌和胰腺癌。然而，由于PARP-Trapping和长期的临床跟踪，PARPi不可避免地产生耐药性并表现出高毒性。为了克服 PARPi 的耐药性和高毒性，人们开发了许多新方法，包括 PROTAC。作为一种事件驱动技术，PROTAC 需要高亲和力、低毒性的弹头，并且在结合过程中没有空间位阻。 Veliparib显示出最低的PARP捕获效果，但由于强烈的空间位阻，很难成为PROTAC的弹头。其他 PARP1 抑制剂表现出较小的空间位阻，但具有较高的 PARP 捕获效果。因此，开发具有高PARP1亲和力、低PARP1捕获且无空间位阻的新型弹头将是有价值的。在这项工作中，我们保留苯并咪唑作为基序以保留低PARP1捕获效应，并用芳环取代吡咯以避免PARP1结合洞中的空间位阻。因此，设计并合成了一系列苯并咪

  DOI：

  10.1016/j.ejmech.2024.116405

文献信息

• Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
  申请人：Abbott Laboratories

  公开号：US20040116518A1

  公开（公告）日：2004-06-17

  The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases and cerebral vasospasm, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

  本发明涉及新型肉桂酰胺化合物，用于治疗炎症和免疫性疾病以及脑血管痉挛，以及含有这些化合物的药物组合物，以及在哺乳动物中抑制炎症或抑制免疫反应的方法。
• Oxazolone derivatives and uses thereof
  申请人：Syntex (U.S.A.) LLC

  公开号：US06355641B1

  公开（公告）日：2002-03-12

  This invention relates to compounds which are generally alpha1B-receptor antagonists, and which are represented by Formula (I): wherein X, Y, and R1 are as defined in the specification, or individual isomers or racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, and methods for their use as therapeutic agents.

  这项发明涉及一般为α1B-受体拮抗剂的化合物，其由式(I)所代表： 其中X、Y和R1如规范中所定义，或者是各个异构体或消旋或非消旋异构体的混合物，或其药学上可接受的盐或溶剂。该发明还涉及含有这种化合物的药物组合物，以及它们作为治疗剂的使用方法。
• CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20160031908A1

  公开（公告）日：2016-02-04

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

  揭示了新颖的化合物以及治疗与异常白细胞召集和/或激活相关的疾病的方法。该方法包括向需要的受试者施用代表的化合物的有效量： 或其生理上可接受的盐。
• Novel imidazopyrimidines-based molecules induce tetramerization of tumor pyruvate kinase M2 and exhibit potent antiproliferative profile
  作者：Sagarkumar Patel、Christoph Globisch、Priyanka Pulugu、Prasoon Kumar、Alok Jain、Amit Shard

  DOI：10.1016/j.ejps.2021.106112

  日期：2022.3

  Discovery of novel and potent lead molecules for the specific therapeutic targets by de novo drug design is still in infancy. Here, we disclose the unprecedented development of imidazopyri(mi)dine-based tumor pyruvate kinase M2 (PKM2) modulators by subsequent link and grow strategy. The most potent modulator 15n acts as a PKM2 activator with an AC50 of 90 nM, with considerable cancer cell-selectivity

  通过从头  药物设计发现针对特定治疗靶点的新型有效先导分子仍处于起步阶段。 在这里，我们通过后续的链接和增长策略披露了基于咪唑并嘧啶 (mi)dine 的肿瘤丙酮酸激酶 M2 (PKM2) 调节剂的前所未有的发展。最有效的调节剂 15n 作为 PKM2 激活剂，AC 50 为 90 nM，具有相当大的癌细胞选择性和膜渗透性。NMR 代谢组学研究还表明，用15n处理会降低 MCF-7 细胞中的乳酸浓度。15n 与两个单体界面相邻的 PKM2 上先前报道的位点结合。在分子动力学 (MD) 模拟研究中，观察到15n在二聚体界面稳定 PKM2，有助于形成具有生物活性的四聚体构象。 还在 3-D 支架上生长的 MCF-7 乳腺癌细胞系上筛选了15n ，与对照相比，结果显示出更好的抗癌潜力，为未来的临床研究铺平了道路。
• New potent 5-HT2A receptor ligands containing an N′-cyanopicolinamidine nucleus: Synthesis and in vitro pharmacological evaluation
  作者：Ferdinando Fiorino、Beatrice Severino、Elisa Magli、Elisa Perissutti、Francesco Frecentese、Antonella Esposito、Giuseppina Maria Incisivo、Antonio Ciano、Paola Massarelli、Cristina Nencini、Vincenzo Santagada、Giuseppe Caliendo

  DOI：10.1016/j.ejmech.2011.11.023

  日期：2012.1

  N′-cyanopicolinamidine derivatives, linked to an arylpiperazine moiety, were prepared and their affinity to serotonin 5-HT1A, 5-HT2A and 5-HT2C receptors were evaluated. The combination of structural elements (heterocyclic nucleus, alkyl chain and 4-substituted piperazine) known to be critical for affinity to 5-HT1A receptors and the proper selection of substituents led to compounds with high specificity

  制备与芳基哌嗪部分连接的N'-氰基吡啶啉am衍生物，并评估它们对5-羟色胺5-HT 1A，5-HT 2A和5-HT 2C受体的亲和力。已知对5-HT 1A受体的亲和力至关重要的结构元素（杂环核，烷基链和4-取代的哌嗪）的组合以及对取代基的正确选择导致了对5-羟色胺能受体具有高特异性和亲和力的化合物。在结合研究中，几个分子在5-HT 2A处显示出纳摩尔和亚纳摩尔范围内的亲和力，而对其他相关受体（5-HT 1A，5-HT 2C，D 1，D2，α 1和α 2）。K i  = 0.000185 nM的N'-氰基-N-（3-（4-（3-氯苯基）哌嗪-1-基）丙基）-吡啶啉olin （4l）是5-HT活性最高的选择性衍生物2A受体与其他5-羟色胺，多巴胺能和肾上腺素能受体相比。